Related Experiment Video
Updated: Jun 4, 2025

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Multifunctional NO supramolecular nanomedicine for thrombus risk reduction and intimal hyperplasia inhibition
Kuangshi Zhou1,2,3, Chengchen Huang1,2,3, Jian Li1,2,3,4
1Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China. minshang@zju.edu.cn.
Abstract:
Cardiovascular diseases (CVDs) are the foremost cause of mortality worldwide, with incidence and mortality rates persistently climbing despite extensive research efforts. Innovative therapeutic approaches are still needed to extend patients' lives and preserve their health. In the present study, novel supramolecular nanomedicine with both nitric oxide (NO) and antioxidant releasing ability was developed to enhance therapeutic efficacy against vascular injuries. Utilizing α-cyclodextrin (α-CD) as a host molecule, the nanomedicine aims to achieve site-specific delivery via targeting peptide rendered selective accumulation. By scavenging ROS and amplifying NO's regulatory effects, the nanomedicine readily restored vascular homeostasis, in both acute and chronic CVDs. It served as a promising solution to overcome the challenges associated with NO-based therapies and may inspire future research studies on new therapies for CVDs.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Clot Retraction and Fibrinolysis

